Information Provided By:
Fly News Breaks for April 8, 2016
ICPT
Apr 8, 2016 | 07:55 EDT
After an FDA panel voted to unanimously recommend accelerated approval of Intercept's OCA drug as a treatment for primary biliary cholangitis Wedbush expects the drug to be approved "on or by" the May 29 PDUFA date. In the wake of the drug's approval, "interest in Intercept as an acquisition target could heat up," Wedbush stated. The firm reiterates a $423 acquisition value and Outperform rating on the shares.
News For ICPT From the Last 2 Days
There are no results for your query ICPT